OPKO Q3 net loss $84.5M; revenues flat; BARDA awards $59M contract for ModeX

OPKO HEALTH, INC.

2024-Q3 EPS reported -$0.16 revenue$681,591,000

Net loss $84.5M ($0.11/sh) vs $86.1M; operating loss improved to $64.4M from $87.8M YoY.
Diagnostics revenue $131.7M (-8% YoY); operating loss improved 41% to $29.1M on cost cuts.
Pharmaceuticals revenue $40.7M (+26% YoY) driven by international sales; RAYALDEE up to $7.3M.
ModeX awarded $59M BARDA contract for multispecific antibodies; up to $109M in milestones.
NGENLA approved in 48 markets; U.S. gross profit sharing began August 2023; cash $138.6M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OPKO HEALTH, INC. reported the quarter ended September 30, 2023 results: revenue $178.6 million.

Period: the quarter ended September 30, 2023
Revenue: $178.6 million
Result: reported results

Exact text from the filing

Consolidated total revenues for the third quarter of 2023 were $178.6 million

View on SEC.gov

Browse all earnings releases →

OPKO HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-030387

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.